Charles Schwab Investment Management Inc Arcellx, Inc. Call Options Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACLX
# of Institutions
186Shares Held
43.4MCall Options Held
73.8KPut Options Held
196K-
Perceptive Advisors LLC New York, NY3.93MShares$244 Million5.74% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.82MShares$237 Million9.96% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$233 Million18.28% of portfolio
-
Black Rock Inc. New York, NY3.07MShares$190 Million0.01% of portfolio
-
Sr One Capital Management, LP2.35MShares$146 Million54.95% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.72B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...